Clinical Trials
15 trialsNCT07386158 2026-02-04
Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
Sun Yat-sen University
Phase 2 Recruiting
NCT04373369 2025-11-03
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT07047001 2025-07-09
Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT03583086 2024-10-08
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
Vanderbilt-Ingram Cancer Center
Phase 1/2 Completed
NCT06577961 2024-08-29
Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Not yet recruiting
NCT06523049 2024-07-26
Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy
West China Hospital
Phase 2 Not yet recruiting
NCT03792958 2022-11-14
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors
AnewPharma
Phase 1 Unknown
NCT04328506 2021-11-26
Bioequivalency Study of CM082 Tablet in Healthy Volunteers
AnewPharma
Phase 1 Completed
NCT03095040 2021-02-08
CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma
AnewPharma
Phase 3 Unknown
NCT03511222 2020-07-29
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Washington University School of Medicine
Phase 1 Terminated
NCT03848611 2020-07-09
CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).
AnewPharma
Phase 2 Unknown
NCT03904719 2020-07-09
CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)
AnewPharma
Phase 2 Unknown
NCT04126668 2020-05-21
A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers
AnewPharma
Phase 1 Completed
NCT01863485 2019-07-05
Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China
AnewPharma
Phase 1 Completed
NCT03286244 2019-02-21
Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer
AnewPharma
Phase 1 Unknown